him from experiencing urine retention, which is a common adverse effect of hyoscyamine in such patients.
avoidable U.S. health care costs each year (1, 2) . Increasing adherence may improve health outcomes and reduce costs even more so than the advent of new medical treatments (1, 3) . However, such efforts have been limited by the lack of objective measures of adherence (3). Electronic adherence monitoring devices (EAMDs) are the most objective and preferred measurement strategy for clinical practice and research but lack independently obtained (versus manufacturerprovided) data on accuracy.
Objective: To assess the accuracy of commercially available EAMDs and help clinicians and researchers select the optimal EAMD based on their needs and goals (4) .
Methods and Findings: This study was exempt from institutional review board review. PubMed/MEDLINE, CINAHL, PsycINFO, and Scopus were searched to identify all EAMDs included in published studies of medication adherence. To maximize the likelihood that all relevant EAMDs were identified, coauthors who are experts in adherence also provided a list of EAMDs with which they were familiar. The systematic review identified 12 EAMDs, and the experts identified an additional 10. Of the 22 EAMDs, 15 were available for purchase and 10 were successfully obtained (3 manufacturers did not reply, 1 manufacturer refused to sell their EAMD, and 1 EAMD was cost-prohibitive [>$500]).
Four of each EAMD were obtained, with 3 devices tested according to a 21-day protocol reflecting a twice-daily medication prescribed 7 days per week. Each protocol simulated 4 adherence patterns: perfect adherence (EAMD opened at 100% of prescribed doses), nonadherence: additional doses (EAMD opened at 5 randomly selected times in addition to prescribed doses [150% of prescribed doses]), nonadherence: missed doses (EAMD opened at 50% of prescribed doses), and device nonuse (EAMD opened at 0% of prescribed doses) (5). All patterns except for device nonuse were tested over 1 of 3 workweeks (Monday through Friday). The EAMDs were not opened on weekends to simulate device nonuse. Each protocol included 25 scheduled openings. Three protocols were generated using a counterbalanced design in which each of the 3 EAMDs of a given model was simultaneously tested for a different adherence pattern.
The date and time of each opening were recorded by the first author on a paper form. A second investigator independently recorded the date and time of a random 10% of openings (intraclass correlation, 1.00). The primary measure of EAMD accuracy was the number of EAMD-registered openings out of 25 that fell within 120 seconds of the date and time recorded on the paper form (4). Table 1 defines additional measures of accuracy. Characteristics of EAMDs (dimensions, data transmission, reminders, notifications, and data access) were obtained from publicly available information. Capacity (defined as the number of 10-mm round tablets and 18-mm oval caplets held by each EAMD) was assessed independently by 2 investigators.
All 3 tested devices of 7 EAMD types registered at least 24 of 25 openings within 120 seconds of the date and time recorded by the investigators. The average discrepancy between the EAMD-registered time and the date and time recorded by the investigators for each device ranged from 3 to Table 2 includes features relevant to usability. Discussion: In this independent evaluation, 7 of 10 EAMDs accurately registered at least 24 of 25 openings. Among these, the EAMD that is "best" for a given clinical program or research study depends on the characteristics of the patient population (medication number and size, medication schedule, and patient preferences). Selecting an EAMD with features that align with patient characteristics may increase patient acceptability and uptake. In addition, clinicians and researchers should consider the degree to which EAMD features are consistent with the patients' geographic location (for example, EAMDs requiring cellular connectivity may not function in areas with limited service), the degree to which EAMD features are consistent with the clinical or research goal of EAMD use (for example, efforts to passively monitor adherence may preclude the use of EAMDs with reminders), and their budget. The costs of EAMDs vary substantially, and pricing information unfortunately is not publicly available for all devices. Interested users thus may need to independently solicit quotes and should note that some manufacturers will only provide quotes that are confidential and/or after obtaining information about budget availability.
This study has limitations. Not all available EAMDs were tested, and testing took place in a controlled laboratory without activating all available features. Evaluating the full functionality, usability, and connectivity of EAMDs will require future study.
In summary, many EAMDs accurately assess medication adherence behavior. To identify the most appropriate EAMD, we encourage clinicians and researchers to consider the characteristics of their patient population and their clinical or research goals.
Meghan E. McGrady, PhD
Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine Cincinnati, Ohio TO THE EDITOR: We appreciate Thorn and colleagues' (1) randomized controlled trial comparing literacy-adapted, simplified group cognitive behavioral therapy (CBT) with group pain education and usual care. As the authors note, chronic pain is a common problem that disproportionately affects groups with low socioeconomic status (SES); finding an effective intervention for these persons is thus essential (1, 2) .
Behavioral economics is a useful lens through which to examine the treatment of chronic pain in populations with low SES. Persons who face scarcity (including those struggling with poverty) are mentally taxed and may have reduced cognitive capacity, or "bandwidth" (3). Although cognitive capacity is traditionally believed to be fixed, research has shown that multiple factors can reduce a person's bandwidth, including poverty (4) . A person who struggles with poverty will have decreased mental resources to devote to issues aside from finances and basic needs (4) and may not have the available cognitive capacity to focus on therapy or education if they are struggling to make ends meet. For example, we have noted that patients with low SES and limited literacy struggle with understanding basic tenets of CBT, such as differentiating among thoughts, feelings, and actions. This concept of bandwidth is also important because the amount required to attend 6 or more CBT sessions, defined as adequate dosage in Thorn and colleagues' study, is considerable for a vulnerable population.
We admire the 75% uptake rate of Thorn and colleagues' CBT intervention in this study. Here we highlight steps that might economize bandwidth and promote the uptake of CBT interventions in patients with low SES. Programs can be simplified to reduce the cognitive burden on available bandwidth while still maintaining the benefits of an intervention (3). In Thorn and colleagues' study, the investigators reduced required bandwidth for participants by using a literacy-adapted CBT program. The LAMP (Learning About My Pain) modules include content that has anecdotally resonated during individual CBT sessions with our patients with low SES, including the connection between stress and pain and the "pain and fear cycle." In addition, we suggest that interventions take place at the beginning of the month after persons receive paychecks to avoid the decreased bandwidth that can occur toward the end of the month as budgets are stretched (4) . Overall, we believe that this low-literacy adaptation of CBT is an important step forward in treating chronic pain in a disproportionately affected population.
IN RESPONSE:
We appreciate that Ms. Rediger and Dr. Miles note that our simplified materials and approaches resonate with their patients with low SES. We sought to test our simplified CBT in low-income clinics, where multiple health and treatment disparities often exist. Although the many challenges associated with poverty can limit patients' ability to understand and use psychosocial treatments, we propose that simplifying treatments makes sense for everyone with a chronic illness. The multiple stressors (and medications) associated with chronic health conditions drain one's cognitive capacity, leaving fewer resources available to understand, remember, and adhere to treatment regimens. Pain itself
